Extensions & Further Applications

Users can adapt the provided valuation tool to assess savings associated with rapid turnaround molecular testing services for different applications than those presented on this website. These include:

New antiviral drugs

Our modelling tool may be extended to incorporate other antiviral drugs in Hep C treatment that have undergone clinical trials and will become available from 2014. These are Simeprivir  (overall SVR 74%), Faldeprivir (overall SVR 73%) and Sofosbuvir (overall SVR 89%).

The user would have to specify in the “Assumptions input sheet” the proportion of overall patients which will be put on the new antiviral treatment, specify the unit costs of this antiviral therapy and its duration.

Application for other disease areas

New generation molecular devices such as the Idylla system have the potential to improve healthcare by disrupting the current patient trajectory by delivering rapid results indispensible for clinical decision making.

Potential disease that could benefit from such testing:

HIV & HBV: similar benefits as case developed in JUMP project:

• Fast identification of failing patients
• Avoid patient to come twice for an appointment
• Avoid to recall failing patient
• Molecular diagnostics has the potential to confirm an HIV and HCV positive antibody assay – which saves time and allows to focus faster on treatment

Flu or other viral respiratory diseases (ex. RSV)

• Rapid identification of patient with Flu versus Influenza Like Syndrome
• Rapid hospitalization of at risk patient

Gynecology/Venerology

• Rapid identification of Chlamydia Trachomatis (CT) and Neisseria
• No need to recall patient

To adapt the modeling tool for other disease areas, users would need to specify in the “Assumptions input sheet” relevant epidemiological data (e.g. prevalence rates), treatments available and annual transition rates. Costs of treatments need to be incorporated in the “Unit costs” worksheets. There is no need to adjust national data in the “Population selection” worksheet, apart from selecting relevant geographical locations. Finally, in the “IDYLLA” worksheet calculations must be adjusted to encompass the savings of not recalling a patient for a repeat visit or of identifying failing patients earlier, whichever is relevant for the particular disease under consideration.